Old Web
English
Sign In
Acemap
>
Paper
>
Once-daily tiotropium Respimat®: safety and tolerability results from five Phase III trials in adults with symptomatic asthma
Once-daily tiotropium Respimat®: safety and tolerability results from five Phase III trials in adults with symptomatic asthma
2016
E Beck
Thomas B. Casale
Nicola A. Hanania
J Haughney
Mark Vandewalker
Eli O. Meltzer
Pierluigi Paggiaro
Michael Engel
Anna Unseld
P Moroni-Zentgraf
Ham Kerstjens
Keywords:
Asthma
Respimat
Physical therapy
Tolerability
Medicine
phase iii trials
Pediatrics
once daily
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]